Gilead upgraded to Buy by Needham as Yeztugo gains physician favor, with sales forecast to reach $6.4 billion by 2035, ...

Most analyst forecasts do not factor into their Gilead valuations Yeztugo's share gains in the growing HIV prophylaxis market ...

Needham upgraded Gilead Sciences (NASDAQ:GILD) to Buy from Hold on Friday, citing a physical survey to suggest that the ...

The FDA has approved the first 100% effective HIV prevention drug, lenacapavir, set to be distributed globally and potentially save millions of lives.

Yeztugo, a twice yearly injection, offers a promising advancement in HIV prevention, but high costs and insurance uncertainties may limit its accessibility.

The WHO’s Director-General described the policy guidelines for Gilead’s twice-yearly drug as the “next best thing” in the ...

HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Gilead researchers and collaborators will present new Phase 3 ...

The World Health Organization (WHO) has included Gilead Sciences' twice-yearly formulation of lenacapavir for pre-exposure ...

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved Yeztugo ®— the company’ s injectable HIV-1 capsid inhibitor— as pre-exposure prophylaxis to ...

Gilead Sciences is pushing full speed ahead with its strategy to ensure global access to its long-acting HIV pre-exposure prophylaxis (PrEP) drug Yeztugo (lenacapavir), tapping the Global Fund to F ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® (lenacapavir)—the company’s injectable HIV-1 capsid inhibitor—as ...